DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 4, 2013, Pages 3052-3057

  Zhang, Qiuhua ^a   Steinle, Jena J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Apoptosis; DNA PK; IGFBP 3; Retinal endothelial cell

Indexed keywords

CASEIN KINASE II; CELL PROTEIN; DNA; DNA DEPENDENT PROTEIN KINASE; GLUCOSE; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 3;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADRENERGIC BETA-AGONISTS; APOPTOSIS; CASEIN KINASES; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA-ACTIVATED PROTEIN KINASE; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MORPHOLINES; PHOSPHORYLATION; RETINA; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84877100427     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11533     Document Type: Article

References (33)

1. Ioacara S, Lichiardopol R, Ionescu-Tirgoviste C, et al. Improvements in life expectancy in type 1 diabetes patients in the last six decades. Diabetes Res Clin Pract. 2009;86:146-151.
2. Bartke A, Chandrashekar V, Dominici F, et al. Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights. Biogerontology. 2003;4:1-8.
3. Thrailkill KM. Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther. 2000;2:69-80.
4. Touskova V, Trachta P, Kavalkova P, et al. Serum concentrations and tissue expression of components of insulin-like growth factor-axis in females with type 2 diabetes mellitus and obesity: the influence of very-low-calorie diet. Mol Cell Endocrinol. 2012;361:172-178.
5. Chang KH, Chan-Ling T, McFarland EL, et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci U S A. 2007;104:10595-10600.
6. Giannini S, Cresci B, Pala L, et al. IGFBPs modulate IGF-I-and high glucose-controlled growth of human retinal endothelial cells. J Endocrinol. 2001;171:273-284.
7. Liu LQ, Sposato M, Liu HY, et al. Functional cloning of IGFBP-3 from human microvascular endothelial cells reveals its novel role in promoting proliferation of primitive CD34{thorn}CD38-hematopoietic cells in vitro. Oncol Res. 2003;13:359-371.
8. Zhang Q, Guy K, Pagadala J, et al. Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels. Invest Ophthalmol Vis Sci. 2012;53:3004-3013.
9. Jarajapu YP, Cai J, Yan Y, et al. Protection of blood retinal barrier and systemic vasculature by insulin-like growth factor binding protein-3. PloS One. 2012;7:e39398.
10. Kim JH, Choi DS, Lee OH, et al. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. Blood. 2011;118:2622-2631.
11. Yamada PM, Lee KW. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 2009;296:C954-976.
12. Baricevic I, Masnikosa R, Lagundzin D, Golubovic V, Nedic O. Alterations of insulin-like growth factor binding protein 3 (IGFBP-3) glycosylation in patients with breast tumours. Clin Biochem. 2010;43:725-731.
13. Firth SM, Baxter RC. Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol. 1999;160:379-387.
14. Beattie J, Phillips K, Shand JH, et al. Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulinlike growth factor binding protein _3/5 (IGFBP-3/5) heparin axis. J Mol Endocrinol. 2005;34:163-175.
15. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem. 1999;274:30215-30221.
16. Huang SS, Leal SM, Chen CL, Liu IH, Huang JS. Identification of insulin receptor substrate proteins as key molecules for the TbetaR-V/LRP-1-mediated growth inhibitory signaling cascade in epithelial and myeloid cells. FASEB J. 2004;18:1719-1721.
17. Chang YS, Kong G, Sun S, et al. Clinical significance of insulinlike growth factor-binding protein-3 expression in stage I nonsmall cell lung cancer. Clin Cancer Res. 2002;8:3796-3802.
18. Hanafusa T, Yumoto Y, Nouso K, et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2002;176:149-158.
19. Bang P, Brismar K, Rosenfeld RG. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130-to 150-kDa ternary complex. J Clin Endocrinol Metab. 1994;78:1119-1127.
20. Santer FR, Bacher N, Moser B, et al. Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Res. 2006;66:3024-3033.
21. Cobb LJ, Liu B, Lee KW, Cohen P. Phosphorylation by DNAdependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3. Cancer Res. 2006; 66:10878-10884.
22. Hollowood AD, Stewart CE, Perks CM, et al. Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-independent actions. J Cell Biochem. 2002;86:583-589.
23. Cobb LJ, Mehta H, Cohen P. Enhancing the apoptotic potential of insulin-like growth factor-binding protein-3 in prostate cancer by modulation of CK2 phosphorylation. Mol Endocrinol. 2009;23:1624-1633.
24. Hardcastle IR, Cockcroft X, Curtin NJ, et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005;48:7829-7846.
25. Kosuge S, Sawano Y, Ohtsuki K. A novel CK2-mediated activation of type II cAMP-dependent protein kinase through specific phosphorylation of its regulatory subunit (RIIalpha) in vitro. Biochem Biophys Res Commun. 2003;310:163-168.
26. Spoerri PE, Caballero S, Wilson SH, Shaw LC, Grant MB. Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest Ophthalmol Vis Sci. 2003;44:365-369.
27. Kielczewski JL, Jarajapu YP, McFarland EL, et al. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res. 2009;105:897-905.
28. Zhang Q, Soderland C, Steinle JJ. Regulation of retinal endothelial cell apoptosis through activation of the IGFBP-3 receptor. Apoptosis. 2013;18:361-368.
29. Leibowitz BJ, Cohick WS. Endogenous IGFBP-3 is required for both growth factor-stimulated cell proliferation and cytokineinduced apoptosis in mammary epithelial cells. J Cell Physiol. 2009;220:182-188.
30. Baxter RC, Skriver L. Altered ligand specificity of proteolysed insulin-like growth factor binding protein-3. Biochem Biophys Res Commun. 1993;196:1267-1273.
31. Schedlich LJ, Nilsen T, John AP, Jans DA, Baxter RC. Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology. 2003;144:1984-1993.
32. Coverley JA, Martin JL, Baxter RC. The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinology. 2000;141:564-570.
33. de Silva HC, Firth SM, Twigg SM, Baxter RC. Interaction between IGF binding protein-3 and TGFb in the regulation of adipocyte differentiation. Endocrinology. 2012;153:4799-4807.